Manatuck Hill Partners LLC Takes $544,000 Position in Boston Scientific Corporation $BSX

Manatuck Hill Partners LLC acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 12,738 shares of the medical equipment provider’s stock, valued at approximately $544,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its stake in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares during the last quarter. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC boosted its holdings in shares of Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after acquiring an additional 1,971 shares in the last quarter. Ieq Capital LLC grew its position in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after acquiring an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC grew its position in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after acquiring an additional 2,556 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 194,522 shares of company stock worth $9,385,210. Insiders own 0.34% of the company’s stock.

Boston Scientific Trading Up 1.7%

Shares of BSX opened at $49.86 on Wednesday. The firm has a market capitalization of $72.26 billion, a PE ratio of 20.19, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The stock’s fifty day simple moving average is $46.44 and its 200-day simple moving average is $57.14.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BSX. Wells Fargo & Company cut their price objective on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research report on Thursday, July 30th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Royal Bank Of Canada reduced their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Finally, Stifel Nicolaus set a $60.00 price objective on shares of Boston Scientific in a research report on Wednesday, July 29th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.